Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04543526
Other study ID # DM-ZOL-01
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date September 1, 2021
Est. completion date November 30, 2024

Study information

Verified date July 2021
Source Duomed
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary purpose of this observational registry is to evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads from Ezisurg Medical when used to create anastomoses during standard and robot-assisted laparoscopic Roux-en-Y Gastric Bypass (RYGB) surgery. Stapler performance during surgery as well as post-operative pain and the clinical efficacy of the procedures will be determined as secondary objectives.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 30, 2024
Est. primary completion date October 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient = 18 years of age at study entry. - Patient and investigator signed and dated the informed consent form prior to the index-procedure. - Patient has a BMI = 35 kg/m2 with one or more related co-morbidity. - Patient has a BMI = 40 kg/m2. - Patient is eligible for standard laparoscopic or for robotic-assisted laparoscopic RYGB surgery. Exclusion Criteria: - Patient is unable / unwilling to provide informed consent. - Patient has a history of bariatric surgery. - Patient is unable to comply with the study protocol or proposed follow-up visits. - Patient has a contra-indication for standard laparoscopic or robot-assisted laparoscopic RYGB surgery.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical). Device for creating anastomoses during standard and robot-assisted laparoscopic RYGB, manufactured by Ezisurg Medical.

Locations

Country Name City State
Belgium Ziekenhuis Oost-Limburg (ZOL) Genk
Belgium Ziekenhuis Maas en Kempen (ZMK) Maaseik

Sponsors (1)

Lead Sponsor Collaborator
Duomed

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety - Conversion rate to laparotomy Number of conversions to laparotomy during the index procedure At index procedure.
Primary Safety - Length of stay at the intensive care unit Number of days at the intensive care unit after the index procedure. At index procedure.
Primary Safety - Length of stay in the hospital by the modified Post-Anesthesia Discharge Scoring System (PADSS) The Modified PADSS guarantees safe discharge. PADSS is based on the assessment of 6 criteria: vital signs (including blood pressure, pulse, temperature and respiratory rate), ambulation, nausea / vomiting, pain, surgical bleeding and fluid intake / output. Each criterion is given a score from 0 to 2. Patients scoring = 9 are considered fit for discharge, provided that the score for vital signs is not lower than 2 and that none of the other five criteria is 0, even if the total score reaches 9. At index procedure.
Primary Safety - Number of re-interventions and number of participants with (serious) adverse events Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo. At index procedure.
Primary Safety - Length of stay at the intensive care unit. Number of days at the intensive care unit after the index procedure. At discharge, up to 1 week.
Primary Safety - Length of stay in the hospital by the modified Post-Anesthesia Discharge Scoring System (PADSS) he Modified PADSS guarantees safe discharge. PADSS is based on the assessment of 6 criteria: vital signs (including blood pressure, pulse, temperature and respiratory rate), ambulation, nausea / vomiting, pain, surgical bleeding and fluid intake / output. Each criterion is given a score from 0 to 2. Patients scoring = 9 are considered fit for discharge, provided that the score for vital signs is not lower than 2 and that none of the other five criteria is 0, even if the total score reaches 9. At discharge, up to 1 week.
Primary Safety - Number of re-interventions and number of participants with (serious) adverse events Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo. At discharge, up to 1 week.
Primary Safety - Number of re-interventions and number of participants with (serious) adverse events Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo. Follow-up 1: 1 month after the procedure.
Primary Safety - Number of re-interventions and number of participants with (serious) adverse events Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo. Follow-up 2: 6 months after the procedure.
Primary Safety - Number of re-interventions and number of participants with (serious) adverse events Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo. Follow-up 3: 12 months after the procedure
Primary Safety - Number of re-interventions and number of participants with (serious) adverse events Number of re-interventions and number of participants with (serious) adverse events = grade II Clavien-Dindo. Follow-up 4: 24 months after the procedure.
Secondary Device performance - Technical success of the surgical procedure performed with the device Number of procedures with technical success defined as bariatric surgery as intended, without technical difficulties and without conversion to laparotomy. At index procedure
Secondary Device performance - Scoring of operator satisfaction Scoring of: easy of intra-abdominal device positioning, grasping/climbing force, sharpness of the blades, staple-line formation, device stability, device maneuverability, battery power, device consistency and reliability, ergonomic design, hemostasis. Each of the aforementioned items receives a score from 0 to 4, with 0 indicating that the user is very unsatisfied and 4 indicating that the user is very satisfied. At index procedure
Secondary Post-operative pain by means of the Visual Analogue Scale (VAS) Assessment of acute post-operative abdominal pain by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain. At index procedure
Secondary Post-operative pain by means of the Visual Analogue Scale (VAS) Assessment of acute post-operative abdominal pain by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain. At discharge, up to 1 week
Secondary Post-operative pain by means of the Visual Analogue Scale (VAS) Assessment of the worst post-operative abdominal pain since discharge by means of the VAS, which contains a 0 to 100 grading scale with 0 equaling no pain and 100 equaling the worst conceivable pain. Follow-up 1: 1 month after the procedure
Secondary Post-operative food tolerance by means of the food tolerance questionnaire Food tolerance by means of the food tolerance questionnaire. The food tolerance questionnaire allows to score the patients' satisfaction regarding food intake and food tolerance after bariatric surgery. The patients' interpretation of food intake is scored between 1 (very poor) and 5 (excellent). A cumulative score, varying between 1 and 27 is derived, with 27 representing an excellent food tolerance. Follow-up 1: 1 month after the procedure
Secondary Post-operative food tolerance by means of the food tolerance questionnaire Food tolerance by means of the food tolerance questionnaire. The food tolerance questionnaire allows to score the patients' satisfaction regarding food intake and food tolerance after bariatric surgery. The patients' interpretation of food intake is scored between 1 (very poor) and 5 (excellent). A cumulative score, varying between 1 and 27 is derived, with 27 representing an excellent food tolerance. Follow-up 2: 6 months after the procedure
Secondary Post-operative food tolerance by means of the food tolerance questionnaire Food tolerance by means of the food tolerance questionnaire. The food tolerance questionnaire allows to score the patients' satisfaction regarding food intake and food tolerance after bariatric surgery. The patients' interpretation of food intake is scored between 1 (very poor) and 5 (excellent). A cumulative score, varying between 1 and 27 is derived, with 27 representing an excellent food tolerance. Follow-up 3: 12 months after the procedure
Secondary Post-operative food tolerance by means of the food tolerance questionnaire Food tolerance by means of the food tolerance questionnaire. The food tolerance questionnaire allows to score the patients' satisfaction regarding food intake and food tolerance after bariatric surgery. The patients' interpretation of food intake is scored between 1 (very poor) and 5 (excellent). A cumulative score, varying between 1 and 27 is derived, with 27 representing an excellent food tolerance. Follow-up 4: 24 months after the procedure
Secondary Post-operative change in weight Weight loss 1 month after the surgical procedure as compared to the patients' weight at baseline. Follow-up 1: 1 month after the procedure
Secondary Post-operative change in weight Weight loss 6 months after the surgical procedure as compared to the patients' weight at baseline. Follow-up 2: 6 months after the procedure
Secondary Post-operative change in weight Weight loss 12 months after the surgical procedure as compared to the patients' weight at baseline. Follow-up 3: 12 months after the procedure
Secondary Post-operative change in weight Weight loss 24 months after the surgical procedure as compared to the patients' weight at baseline. Follow-up 4: 24 months after the procedure
Secondary Number of participants with a post-operative change of cormorbidities Comorbidities (diabetes mellitus, peripheral arterial disease, coronary arterial disease, sleep disordered breathing, hypertension, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, asthma, congestive heart failure, degenerative joint disease, gastroesophageal reflux, chronic obstructive pulmonary disease, use of immunosuppressants) 12 months after the surgical procedure as compared to the patients' comorbidities at baseline. Follow-up 3: 12 months after the procedure
Secondary Number of participants with a post-operative change of cormorbidities Comorbidities (diabetes mellitus, peripheral arterial disease, coronary arterial disease, sleep disordered breathing, hypertension, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, asthma, congestive heart failure, degenerative joint disease, gastroesophageal reflux, chronic obstructive pulmonary disease, use of immunosuppressants) 24 months after the surgical procedure as compared to the patients' comorbidities at baseline. Follow-up 4: 24 months after the procedure
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2